Scholars Central

Conference abstractPublished 6 Jul 2022

Psychomotor dysfunction in Rasopathies

Authors: Ramachandran Muthiah

Morning star hospital, Marthandam, Kanyakumari District, India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Rasopathies are developmental disorders characterised by postnatal growth retardation with delayed skeletal maturation, psychomotor dysfunction, cutis lax, and acanthosis Nigerians and resulting from germ line mutations of the proto-oncogene HRAS. Many of these mutations affect SHP2, SOS1, RAS, RAF and MEK proteins. Dr White says a group of related disorders including Costello syndrome, Noonan syndrome (NS), cardiofaciocutaneous (CFC) syndrome, and neurofibromatosis 1 (NF1), caused by abnormal functioning of Ras‐mitogen‐activated protein kinase signalling pathway that controls cell proliferation, differentiation and survival. In this pathway, Ras, a GTPase, transmits extracellular signalling from receptor tyrosine kinases to two serine/threonine kinases (Raf and MEK) and to the activation of MAPKs. Psychosomatic dysfunction is a common feature of rasopathies. Isoprenylation involves the enzyme farnesyl transferees (FTase) transferring a farnesyl group from farnesyl pyrophosphate (FPP) to the pre-Ras protein. Pathway modulators or small molecule inhibitors such as statins causes significant improvement in verbal and nonverbal memory, visual attention & efficacy by inhibiting the posttranscriptional lipid modification of RAS. RAF-1 inhibition by C-type Natriuretic Peptide (CNP) improved bone growth in preclinical animal models and it is a potential targeted therapeutic drug to improve the stature of patients. Gene correction of the gremlin mutations to restore normal protein functions is anticipated as a new therapeutic option. Oxidative stress and free radicals- determine non-neoplastic clinical features such as elastin anomalies, alteration of skin and appendages, developmental retardation and cardiac defects. PAR therapy (potassium acerbate with ribose).Causes a reduction in oxidative stress biomarkers in parallel with improvement of clinical features. It combines the antioxidant action of vitamin C with stabilizing intracellular effects of potassium and causes improvement of skin and appendage lesions, better evolution of psychomotor development, no Progression of heart hypertrophy, nor tumour development. It is low cost, no side-effects, orally administered and useful for all genetic syndromes.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Alcoholism & Drug Dependence.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Alcoholism & Drug Dependence
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Ramachandran Muthiah”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels